LONDON (Reuters) - - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck - seems bound to win.
But others drugmakers, such as Johnson & Johnson and GlaxoSmithKline, are also in the running - and must stick with it even though they are unlikely to make a profit, experts say, because the world needs more than one Ebola vaccine.
